Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2024 16:30 ET
|
Mural Oncology, Inc.
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
January 08, 2024 07:00 ET
|
Mural Oncology, Inc.
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
November 15, 2023 07:00 ET
|
Mural Oncology, Inc.
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies